AU2016331955B2 - Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors - Google Patents

Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors Download PDF

Info

Publication number
AU2016331955B2
AU2016331955B2 AU2016331955A AU2016331955A AU2016331955B2 AU 2016331955 B2 AU2016331955 B2 AU 2016331955B2 AU 2016331955 A AU2016331955 A AU 2016331955A AU 2016331955 A AU2016331955 A AU 2016331955A AU 2016331955 B2 AU2016331955 B2 AU 2016331955B2
Authority
AU
Australia
Prior art keywords
cancer
compound
subject
hours
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016331955A
Other languages
English (en)
Other versions
AU2016331955A1 (en
Inventor
Mohammed ASMAL
Scott Zachary Fields
Peter Littlewood
John Robert Pollard
Philip Michael Reaper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2016331955A1 publication Critical patent/AU2016331955A1/en
Application granted granted Critical
Publication of AU2016331955B2 publication Critical patent/AU2016331955B2/en
Priority to AU2022256154A priority Critical patent/AU2022256154B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016331955A 2015-09-30 2016-09-30 Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors Ceased AU2016331955B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022256154A AU2022256154B2 (en) 2015-09-30 2022-10-20 Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201562235393P 2015-09-30 2015-09-30
US62/235,393 2015-09-30
US201562251640P 2015-11-05 2015-11-05
US62/251,640 2015-11-05
US201662287136P 2016-01-26 2016-01-26
US62/287,136 2016-01-26
US201662303153P 2016-03-03 2016-03-03
US62/303,153 2016-03-03
US201662323055P 2016-04-15 2016-04-15
US62/323,055 2016-04-15
US201662345191P 2016-06-03 2016-06-03
US62/345,191 2016-06-03
PCT/US2016/054996 WO2017059357A1 (en) 2015-09-30 2016-09-30 Method for treating cancer using a combination of dna damaging agents and atr inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022256154A Division AU2022256154B2 (en) 2015-09-30 2022-10-20 Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Publications (2)

Publication Number Publication Date
AU2016331955A1 AU2016331955A1 (en) 2018-04-12
AU2016331955B2 true AU2016331955B2 (en) 2022-07-21

Family

ID=58427990

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016331955A Ceased AU2016331955B2 (en) 2015-09-30 2016-09-30 Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
AU2022256154A Active AU2022256154B2 (en) 2015-09-30 2022-10-20 Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022256154A Active AU2022256154B2 (en) 2015-09-30 2022-10-20 Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Country Status (11)

Country Link
US (2) US11464774B2 (https=)
EP (1) EP3355926B8 (https=)
JP (1) JP7187308B2 (https=)
KR (1) KR102678021B1 (https=)
AU (2) AU2016331955B2 (https=)
CA (1) CA3000684C (https=)
HK (1) HK1258570A1 (https=)
IL (1) IL258410A (https=)
MX (1) MX395066B (https=)
RU (1) RU2768621C1 (https=)
WO (1) WO2017059357A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
EP3936153B1 (en) 2016-01-11 2024-08-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
RU2758669C2 (ru) 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
EP3554494A4 (en) 2016-12-19 2021-02-17 Cellixbio Private Limited INFLAMMATION TREATMENT COMPOSITIONS AND METHODS
SG11202005156WA (en) * 2017-12-29 2020-07-29 Vertex Pharma Methods of cancer treatment using an atr inhibitor
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
CA3100276A1 (en) 2018-06-06 2019-12-12 Massachusetts Institute Of Technology Circular rna for translation in eukaryotic cells
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
EP3866785A1 (en) * 2018-10-15 2021-08-25 Merck Patent GmbH Combination therapy utilizing dna alkylating agents and atr inhibitors
WO2020237227A1 (en) 2019-05-22 2020-11-26 Massachusetts Institute Of Technology Circular rna compositions and methods
AU2020397956A1 (en) 2019-12-04 2022-07-07 Orna Therapeutics, Inc. Circular RNA compositions and methods
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
CN115955962B (zh) * 2020-07-08 2024-07-12 代顿治疗股份公司 用于治疗淋巴肿瘤的沙铂
EP4323362B1 (en) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
TW202309299A (zh) * 2021-07-12 2023-03-01 大陸商北京輯因醫療科技有限公司 鑒定癌細胞中藥物敏感基因和耐藥基因的方法
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
KR20250016691A (ko) 2023-07-24 2025-02-04 숙명여자대학교산학협력단 호르네린을 포함하는 암의 예후 예측용 바이오 마커 조성물 및 이의 용도
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044802A1 (en) * 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof

Family Cites Families (361)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309430A (en) 1980-06-27 1982-01-05 Merck & Co., Inc. Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same
JPS62270623A (ja) 1985-12-07 1987-11-25 Daicel Chem Ind Ltd ビス（４−アミノフエニル）ピラジンおよびその製法、ならびにポリイミドおよびその製法
JPS63208520A (ja) 1987-02-26 1988-08-30 Terumo Corp ピラジン誘導体を含有する血小板凝集抑制剤
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
JPH0272372A (ja) 1988-09-07 1990-03-12 Konica Corp 電子写真感光体
JPH0272370A (ja) 1988-09-07 1990-03-12 Konica Corp 電子写真感光体
JPH0374370A (ja) 1989-08-16 1991-03-28 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤または抗炎症剤
JP2597917B2 (ja) 1990-04-26 1997-04-09 富士写真フイルム株式会社 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料
US5572248A (en) 1994-09-19 1996-11-05 Teleport Corporation Teleconferencing method and system for providing face-to-face, non-animated teleconference environment
EP0824533B1 (de) 1995-05-09 2001-11-14 Basf Aktiengesellschaft PYRAZOLO- 1,5a]-PYRIMIDINE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG
EP0914318A1 (en) 1996-05-11 1999-05-12 Kings College London Pyrazines
HU228962B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo triazines, pharmaceutical compositions containing them and use of the compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
JP4026876B2 (ja) 1996-09-05 2007-12-26 日本食品化工株式会社 発光性シクロデキストリン誘導体及びその製造方法
JPH10218881A (ja) 1997-02-03 1998-08-18 Pola Chem Ind Inc 新規なピロロピラゾロピリミジン誘導体
JP2002241379A (ja) 1997-03-21 2002-08-28 Dainippon Pharmaceut Co Ltd ３−オキサジアゾリルキノキサリン誘導体
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
WO1999044609A1 (en) 1998-03-03 1999-09-10 Merck & Co., Inc. FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS
DE19826671A1 (de) 1998-06-16 1999-12-23 Hoechst Schering Agrevo Gmbh 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
EP1097933A4 (en) 1998-07-16 2001-11-07 Shionogi & Co PYRIMIDINE DERIVATIVES HAVING ANTI-TUMOR ACTIVITY
US7023913B1 (en) 2000-06-14 2006-04-04 Monroe David A Digital security multimedia sensor
OA11749A (en) 1999-01-11 2005-07-19 Agouron Pharma Tricyclic inhibitors of poly(adp-ribose)polymerases.
US6790935B1 (en) 1999-02-05 2004-09-14 Debiopharm S.A. Cyclosporin derivatives and method for the production of said derivatives
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6738073B2 (en) 1999-05-12 2004-05-18 Imove, Inc. Camera system with both a wide angle view and a high resolution view
US6479504B1 (en) 1999-06-16 2002-11-12 The University Of Iowa Research Foundation Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
US7015954B1 (en) 1999-08-09 2006-03-21 Fuji Xerox Co., Ltd. Automatic video system using multiple cameras
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2001302666A (ja) 1999-09-21 2001-10-31 Nissan Chem Ind Ltd アゾール縮合ヘテロ環アニライド化合物及び除草剤
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP1237880B1 (en) 1999-12-17 2008-01-23 Novartis Vaccines and Diagnostics, Inc. Pyrazine based inhibitors of glycogen synthase kinase 3
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
AU2001264932A1 (en) 2000-05-26 2001-12-11 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
JP2002072370A (ja) 2000-08-29 2002-03-12 Fuji Photo Optical Co Ltd ペーパーマガジン及び写真焼付装置
JP2002072372A (ja) 2000-09-04 2002-03-12 Fuji Photo Film Co Ltd 画像形成用シート体の切断装置
US6829391B2 (en) 2000-09-08 2004-12-07 Siemens Corporate Research, Inc. Adaptive resolution system and method for providing efficient low bit rate transmission of image data for distributed applications
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
CZ304344B6 (cs) 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US6420637B1 (en) 2001-01-29 2002-07-16 Asgrow Seed Company L.L.C. Plants and seeds of corn variety I389972
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
US8085293B2 (en) 2001-03-14 2011-12-27 Koninklijke Philips Electronics N.V. Self adjusting stereo camera system
US6759657B2 (en) 2001-03-27 2004-07-06 Kabushiki Kaisha Toshiba Infrared sensor
JPWO2002080899A1 (ja) 2001-03-30 2005-01-06 エーザイ株式会社 消化器疾患治療剤
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
CA2446380A1 (en) 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
JP2003074370A (ja) 2001-09-05 2003-03-12 Suzuki Motor Corp エンジンのベルト保護装置
US7145002B2 (en) 2001-09-26 2006-12-05 Merck & Co. Inc. Crystalline forms of carbapenem antibiotics and methods of preparation
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003037900A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazolopyrimidines
AU2002343557A1 (en) 2001-11-21 2003-06-10 Pharmacia And Upjohn Company Substituted aryl 1,4-pyrazine derivatives
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1472245A2 (en) 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
EP1505068A4 (en) 2002-04-23 2008-03-19 Shionogi & Co PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND INHIBITOR OF NAD (P) H OXIDASE CONTAINING SAID DERIVATIVE
US7043079B2 (en) 2002-04-25 2006-05-09 Microsoft Corporation “Don't care” pixel interpolation
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
CA2482838A1 (en) 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
US7196111B2 (en) 2002-06-04 2007-03-27 Schering Corporation Pyrazolo[1,5a]pyrimidine compounds as antiviral agents
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
KR20050057139A (ko) 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
WO2004022561A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US7601724B2 (en) 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
CA2497444C (en) 2002-09-04 2010-11-30 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY137843A (en) 2002-09-04 2009-03-31 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
US20040075741A1 (en) 2002-10-17 2004-04-22 Berkey Thomas F. Multiple camera image multiplexer
US7385626B2 (en) 2002-10-21 2008-06-10 Sarnoff Corporation Method and system for performing surveillance
US20040100560A1 (en) 2002-11-22 2004-05-27 Stavely Donald J. Tracking digital zoom in a digital video camera
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
CA2512683C (en) 2003-01-09 2010-03-16 Pfizer Inc. Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
CA2517256C (en) 2003-02-26 2013-04-30 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
JP4564485B2 (ja) 2003-02-28 2010-10-20 帝人ファーマ株式会社 ピラゾロ［１，５−ａ］ピリミジン誘導体
US7684624B2 (en) 2003-03-03 2010-03-23 Smart Technologies Ulc System and method for capturing images of a target area on which information is recorded
CA2517720A1 (en) 2003-03-11 2004-09-23 Pfizer Products Inc. Pyrazine compounds as transforming growth factor (tgf) inhibitors
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2006520794A (ja) 2003-03-21 2006-09-14 スミスクライン ビーチャム コーポレーション 化合物
WO2004084824A2 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
GB2400514B (en) 2003-04-11 2006-07-26 Hewlett Packard Development Co Image capture method
US20060252741A1 (en) 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2004103991A1 (en) 2003-05-20 2004-12-02 'chemical Diversity Research Institute', Ltd. 2-substituted piperidines, focused library and a pharmaceutical compound
US20050123902A1 (en) 2003-05-21 2005-06-09 President And Fellows Of Harvard College Human papillomavirus inhibitors
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US7986339B2 (en) 2003-06-12 2011-07-26 Redflex Traffic Systems Pty Ltd Automated traffic violation monitoring and reporting system with combined video and still-image data
JP2005020227A (ja) 2003-06-25 2005-01-20 Pfu Ltd 画像圧縮装置
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
KR20060070572A (ko) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
US7807696B2 (en) 2003-10-07 2010-10-05 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
KR20060123403A (ko) 2003-12-01 2006-12-01 쿠도스 파마슈티칼스 리미티드 암 치료를 위한 ｄｎａ 손상 수복 억제제
US20050116968A1 (en) 2003-12-02 2005-06-02 John Barrus Multi-capability display
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
WO2005058876A1 (en) 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases
BRPI0418351A (pt) 2004-01-05 2007-05-08 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
EP1715867A4 (en) 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
EP1720879A2 (de) 2004-02-25 2006-11-15 Basf Aktiengesellschaft Azolopyrimidin-verbindungen und ihre verwendung zur bekämpfung von schadpilzen
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
US20050276765A1 (en) 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
MX2007001126A (es) 2004-07-27 2007-09-25 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
BR122020017756B1 (pt) 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
BRPI0514687A (pt) 2004-08-26 2008-06-17 Pfizer compostos amino heteroarila como inibidores de proteìna tirosina cinase
US7730406B2 (en) 2004-10-20 2010-06-01 Hewlett-Packard Development Company, L.P. Image processing system and method
WO2006047504A1 (en) 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Aromatic amides as inhibitors of c-fms kinase
ATE482213T1 (de) 2004-11-04 2010-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
WO2006053342A2 (en) 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
EP1814883A1 (en) 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
JP4810669B2 (ja) 2004-11-25 2011-11-09 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
WO2006071548A2 (en) 2004-12-27 2006-07-06 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US20060156482A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
CA2598456A1 (en) 2005-02-16 2006-08-24 Schering Corporation Heterocyclic substituted piperazines with cxcr3 antagonist activity
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
HRP20100678T1 (hr) 2005-03-29 2011-02-28 Icos Corporation Derivati heteroariluree korisni kao inhibitori chk1
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
JP5033119B2 (ja) 2005-04-25 2012-09-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キナーゼ阻害剤としての新規アザ複素環化合物
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
CA2608890C (en) 2005-05-20 2011-08-02 Alantos-Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US20070155737A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
AU2006258101A1 (en) 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
CN101258142A (zh) 2005-08-02 2008-09-03 莱西肯医药有限公司 作为蛋白激酶抑制剂的2-氨基芳基吡啶
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
US7394926B2 (en) 2005-09-30 2008-07-01 Mitutoyo Corporation Magnified machine vision user interface
CN101316847A (zh) 2005-10-06 2008-12-03 先灵公司 用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物
US20070082900A1 (en) 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
CN101321760A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
TWI333953B (en) 2005-10-06 2010-12-01 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
US7806604B2 (en) 2005-10-20 2010-10-05 Honeywell International Inc. Face detection and tracking in a wide field of view
CA2626789A1 (en) 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
AU2006305104B2 (en) 2005-10-21 2009-10-22 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
TW200736260A (en) 2005-11-10 2007-10-01 Smithkline Beecham Corp Inhibitors of Akt activity
WO2007063012A1 (en) 2005-12-01 2007-06-07 F. Hoffmann-La Roche Ag Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors
EP1970377A4 (en) 2005-12-09 2013-02-27 Meiji Seika Kaisha LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THIS AS AN ACTIVE SUBSTANCE
JP2009519937A (ja) 2005-12-14 2009-05-21 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 無脊椎有害生物防除用イソオキサゾリン
EP1962853A1 (en) 2005-12-22 2008-09-03 Alcon Research, Ltd. (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
ITMI20060311A1 (it) 2006-02-21 2007-08-22 Btsr Int Spa Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
ES2336625T3 (es) 2006-03-22 2010-04-14 Vertex Pharmaceuticals Incorporated Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.
CA2647543A1 (en) 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
US7574131B2 (en) 2006-03-29 2009-08-11 Sunvision Scientific Inc. Object detection system and method
CN101454314A (zh) 2006-03-31 2009-06-10 先灵公司 激酶抑制剂
BRPI0712016A2 (pt) 2006-05-22 2011-12-27 Schering Corp pirazolo[1,5-a]pirimidinas
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
CA2654358A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
JP2009541323A (ja) 2006-06-22 2009-11-26 マリンクロット インコーポレイテッド 拡張された共役を有するピラジン誘導体およびその使用
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
EP2450350A1 (en) 2006-10-04 2012-05-09 F. Hoffmann-La Roche AG 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
ATE543819T1 (de) 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
WO2008060907A2 (en) 2006-11-10 2008-05-22 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
WO2008063671A2 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
US20080132698A1 (en) 2006-11-30 2008-06-05 University Of Ottawa Use of N-oxide compounds in coupling reactions
EP2125808A2 (en) 2006-12-15 2009-12-02 Bayer Schering Pharma Aktiengesellschaft 3-h-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP2125781A2 (en) 2006-12-20 2009-12-02 Amgen Inc. Substituted heterocycles and methods of use
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
MY146638A (en) 2007-04-10 2012-09-14 Bayer Cropscience Ag Insecticidal aryl isoxazoline derivatives
JP2008260691A (ja) 2007-04-10 2008-10-30 Bayer Cropscience Ag 殺虫性アリールイソオキサゾリン誘導体
PE20090288A1 (es) 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CN101743003A (zh) 2007-05-25 2010-06-16 阿斯利康(瑞典)有限公司 用于治疗癌症的chk和parp抑制剂的组合
EP2014661A1 (de) 2007-06-13 2009-01-14 Bayer CropScience AG Heterocyclisch substituierte Heterocyclyl-carbonsäurederivate
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
JP2009027904A (ja) 2007-06-19 2009-02-05 Hitachi Ltd 回転電機
EP2012409A2 (en) 2007-06-19 2009-01-07 Hitachi, Ltd. Rotating electrical machine
EP2157090A4 (en) 2007-06-21 2011-09-07 Taisho Pharmaceutical Co Ltd PYRAZINAMIDE COMPOUND
CN101784269A (zh) 2007-06-26 2010-07-21 莱西肯医药有限公司 治疗由5-羟色胺介导的疾病和病症的方法
WO2009005638A2 (en) 2007-06-27 2009-01-08 Merck & Co., Inc. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
WO2009006580A1 (en) 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
RS54303B1 (sr) 2007-07-19 2016-02-29 Lundbeck, H., A/S 5-člani heterociklični amidi i srodna jedinjenja
JP5241834B2 (ja) 2007-07-19 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての複素環アミド化合物
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
BRPI0815042A2 (pt) 2007-08-01 2015-02-10 Pfizer Compostos de pirazol
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
WO2009037247A1 (en) 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
ATE523508T1 (de) 2007-10-25 2011-09-15 Astrazeneca Ab Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate
MX2010005950A (es) 2007-11-28 2010-06-17 Schering Corp 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa.
WO2009075790A1 (en) 2007-12-07 2009-06-18 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors for intra-articular application
NZ586662A (en) 2007-12-19 2012-08-31 Vertex Pharma PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
JP5989965B2 (ja) 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009099982A1 (en) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
JP5368485B2 (ja) 2008-02-25 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼインヒビター
AU2009218609A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
CA2716223A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
ATE522536T1 (de) 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
JP2011513332A (ja) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
ES2413806T3 (es) 2008-03-20 2013-07-17 Amgen Inc. Moduladores de la aurora cinasa y método de uso
US20110112144A1 (en) 2008-04-28 2011-05-12 Astrazeneca Ab Methods of preparing substituted heterocycles
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
GB0814364D0 (en) 2008-08-05 2008-09-10 Eisai London Res Lab Ltd Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
AU2009279936A1 (en) 2008-08-05 2010-02-11 Banyu Pharmaceutical Co., Ltd. Therapeutic compounds
ES2625817T3 (es) 2008-08-06 2017-07-20 Medivation Technologies, Inc. Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
CN102223798A (zh) 2008-09-24 2011-10-19 巴斯夫欧洲公司 用于防治无脊椎动物害虫的吡唑化合物
JP2010077286A (ja) 2008-09-26 2010-04-08 Aica Kogyo Co Ltd シリコーン樹脂組成物および粘着フィルム
JP2012506381A (ja) 2008-10-21 2012-03-15 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−ＭＥＴタンパク質キナーゼ阻害剤
CN102271515B (zh) 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
KR20170015566A (ko) 2008-11-10 2017-02-08 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
CA2744498C (en) 2008-11-25 2017-10-24 University Of Rochester Mlk inhibitors and methods of use
KR101361858B1 (ko) 2008-12-05 2014-02-12 에프. 호프만-라 로슈 아게 피롤로피라지닐 우레아 키나아제 저해제
ES2663222T3 (es) 2008-12-19 2018-04-11 Vertex Pharmaceuticals Incorporated Derivados de pirazina útiles como inhibidores de la quinasa ATR
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
CA2748099C (en) 2008-12-22 2017-02-28 Array Biopharma Inc. 7-phenoxychroman carboxylic acid derivatives
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
SG173027A1 (en) 2009-01-30 2011-08-29 Toyama Chemical Co Ltd N-acyl anthranilic acid derivative or salt thereof
JP5353279B2 (ja) 2009-02-06 2013-11-27 Ｊｎｃ株式会社 セレンテラミド又はその類縁体の製造方法
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
KR20110132564A (ko) 2009-02-11 2011-12-08 선오비온 파마슈티컬스 인코포레이티드 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법
CN101537007A (zh) 2009-03-18 2009-09-23 中国医学科学院血液病医院（血液学研究所） N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
DK2454892T3 (en) 2009-07-13 2015-04-20 Widex As HEARING-AID adapted to detect brain waves and a method for HOW TO ADAPT a hearing aid
CA2767091A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyrazine inhibitors of kinases
US8674109B2 (en) 2009-08-07 2014-03-18 Dow Agrosciences, Llc. Pesticidal compositions
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
JP2011042639A (ja) 2009-08-24 2011-03-03 Kowa Co ビフェニルピラジン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
WO2011025706A2 (en) 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
HRP20160967T1 (hr) 2009-10-06 2016-10-07 Millennium Pharmaceuticals, Inc. Heterociklički spojevi korisni kao pdk1 inhibitori
CA2780633C (en) 2009-11-13 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
CN102762208A (zh) 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环
HUE027946T2 (en) 2010-01-18 2016-11-28 Medicines For Malaria Venture Mmv New anti-malaria drugs
SG184073A1 (en) 2010-03-18 2012-10-30 Pasteur Institut Korea Anti-infective compounds
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
WO2011121096A1 (en) 2010-03-31 2011-10-06 Dkfz Deutsches Krebsforschungszentrum PYRAZOL[1,5-a]PYRIMIDINE DERIVATIVES AS WNT PATHWAY ANTAGONISTS
EP2556060A1 (en) 2010-04-08 2013-02-13 Ah Usa 42 Llc Substituted 3,5- diphenyl-isoxazoline derivatives as insecticides and acaricides
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
JP5856151B2 (ja) 2010-05-12 2016-02-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013529200A (ja) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013526539A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用なピラジン
CN102906095A (zh) 2010-05-20 2013-01-30 弗·哈夫曼-拉罗切有限公司 作为syk和jak抑制剂的吡咯并吡嗪衍生物
CA2799904A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
CA2803802A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
MA34392B1 (fr) 2010-06-24 2013-07-03 Gilead Sciences Inc Pyrimidines en tant qu'agents antiviraux
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
EP2407478A1 (en) 2010-07-14 2012-01-18 GENETADI Biotech, S.L. New cyclotetrapeptides with pro-angiogenic properties
JP5782238B2 (ja) 2010-07-30 2015-09-24 ルネサスエレクトロニクス株式会社 電圧検出回路及びその制御方法
WO2012022045A1 (en) 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
ES2621857T3 (es) 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
DK2649075T3 (en) 2010-12-08 2018-07-30 Us Health SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
AR085607A1 (es) 2011-03-04 2013-10-16 Lexicon Pharmaceuticals Inc Inhibidores de la mst1 quinasa y metodos para su utilizacion
US8962623B2 (en) 2011-03-04 2015-02-24 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
JP2014510151A (ja) 2011-04-05 2014-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物
KR20140093610A (ko) 2011-04-21 2014-07-28 재단법인 한국파스퇴르연구소 소염 화합물
ES2583086T3 (es) 2011-04-21 2016-09-19 Bayer Intellectual Property Gmbh Pirazolopiridinas sustituidas con fluoroalquilo y su uso
CA2836417A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
WO2012178124A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
WO2013052263A2 (en) 2011-09-16 2013-04-11 Microbiotix, Inc. Antifungal compounds
KR20140084112A (ko) 2011-09-30 2014-07-04 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
WO2013049859A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SG10201606774UA (en) 2011-09-30 2016-10-28 Vertex Pharma Processes for making compounds useful as inhibitors of atr kinase
WO2013049719A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
WO2013071085A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071088A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
SG10201701101YA (en) 2012-04-02 2017-04-27 Cytokinetics Inc Methods for improving diaphragm function
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
RU2659786C2 (ru) 2012-05-15 2018-07-04 Кансер Ресёрч Текнолоджи Лимитед 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
US20130317021A1 (en) 2012-05-23 2013-11-28 Savira Pharmaceuticals Gmbh Heterocyclic pyrimidine carbonic acid derivatives which are useful in the treatment, amelioration or prevention of a viral disease
RU2014143250A (ru) 2012-05-23 2016-07-20 Савира Фармасьютикалз Гмбх Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
KR20150039832A (ko) 2012-08-06 2015-04-13 사피라 파르마슈티칼즈 게엠베하 디하이드록시피리미딘 탄산 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도
EP2895475B1 (en) 2012-08-09 2016-11-09 VIIV Healthcare UK (No.5) Limited Tricyclic amidine derivatives as hiv attachment inhibitors
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
EP2895472B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
IN2015DN01061A (https=) 2012-08-17 2015-06-26 Bayer Cropscience Ag
CN104583197B (zh) 2012-08-24 2017-05-17 霍夫曼-拉罗奇有限公司 新型双环吡啶衍生物
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
US9475816B2 (en) 2012-09-07 2016-10-25 Takeda Pharmaceutical Company Limited Substituted-1,4-dihydropyrazolo[4,3-b]indoles
WO2014042433A2 (en) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
US8999632B2 (en) * 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP6465803B2 (ja) 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
AU2013334635B2 (en) 2012-10-24 2018-12-06 Becton, Dickinson And Company Hydroxamate substituted azaindoline-cyanine dyes and bioconjugates of the same
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
JP6096005B2 (ja) 2013-02-26 2017-03-15 リンテック株式会社 シート剥離装置および剥離方法
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US20150158868A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
DK3077397T3 (da) 2013-12-06 2019-12-16 Vertex Pharma 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
JP2016540773A (ja) 2013-12-06 2016-12-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
PL3152212T3 (pl) 2014-06-05 2020-06-15 Vertex Pharmaceuticals Inc. Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044802A1 (en) * 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FOKAS et al., "Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation", Cell Death & Disease., (2012-12-06), vol. 3, pages 1 - 10 *

Also Published As

Publication number Publication date
HK1258570A1 (zh) 2019-11-15
KR20180054657A (ko) 2018-05-24
EP3355926B1 (en) 2025-12-24
AU2022256154B2 (en) 2024-12-19
MX2018003657A (es) 2018-04-30
AU2022256154A1 (en) 2022-11-24
US20180303829A1 (en) 2018-10-25
CA3000684A1 (en) 2017-04-06
IL258410A (en) 2018-05-31
RU2768621C1 (ru) 2022-03-24
JP7187308B2 (ja) 2022-12-12
AU2016331955A1 (en) 2018-04-12
CA3000684C (en) 2024-10-29
KR102678021B1 (ko) 2024-06-26
US20230106592A1 (en) 2023-04-06
JP2018529713A (ja) 2018-10-11
MX395066B (es) 2025-03-24
WO2017059357A1 (en) 2017-04-06
EP3355926A1 (en) 2018-08-08
EP3355926B8 (en) 2026-04-22
US11464774B2 (en) 2022-10-11
EP3355926A4 (en) 2019-08-21

Similar Documents

Publication Publication Date Title
AU2022256154B2 (en) Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CN107072987B (zh) Chk1和atr抑制剂的组合在制备治疗癌症的药物中的用途
US11980633B2 (en) Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
US11529350B2 (en) Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
US20240217970A1 (en) Phthalimido cereblon complex binders and transcription factor degraders and methods of use
JP7758369B2 (ja) Ｇａｓ４１阻害剤及びその使用方法
JP2024529485A (ja) イミダゾ［１，２－ｂ］ピリダジニル化合物及びその使用
US20230295167A1 (en) Potent and selective inhibitors of her2
CA3038657C (en) Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
US20230226196A1 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
WO2024227026A1 (en) Heterocyclic compounds as parp1 inhibitors
TW202304925A (zh) （呋喃并嘧啶—４—基）哌𠯤化合物及其用途
HK40067698A (en) Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired